Rainer Claus

This study uses pan-cancer phosphoproteomics to identify therapeutic targets and improve precision oncology by analyzing 1,998 tumor samples and developing new scores for kinase activity and immune response.

This study introduces PEDRA, an ex vivo drug response assay that identifies patient-specific treatment options in metastatic biopsies, outperforming prior therapies and informing immune responses.

This paper develops an AI model to detect unstained cell cultures in real-time, achieving high accuracy in distinguishing cell lines and monitoring drug responses.